RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 47 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 11, 2024 |
Jan. 31, 2022 |
Jul. 31, 2020 |
Mar. 31, 2019 |
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
Dec. 31, 2023 |
Apr. 30, 2022 |
Aug. 31, 2025 |
May 31, 2025 |
Dec. 31, 2024 |
Apr. 12, 2024 |
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Research and development expenses | $ 105,576 | $ 123,429 | $ 156,558 | $ 1,242,101 | ||||||||||
| Proceeds from convertible debt | 200,000 | 1,475,000 | ||||||||||||
| Debt funded to Marizyme | 1,800,000 | 1,800,000 | $ 690,000 | |||||||||||
| Short term debt | $ 3,000,000.0 | $ 2,300,000 | ||||||||||||
| License Agreement [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Reimbursement of patent | $ 160,000 | |||||||||||||
| License costs | 0 | 0 | 0 | 2,000 | ||||||||||
| Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Reimbursement of research expenses | $ 693,000 | $ 2,900,000 | ||||||||||||
| License and sponsored research agreement terms | In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones | |||||||||||||
| Revenue | $ 500,000,000 | $ 500,000,000 | ||||||||||||
| Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Upfront license fee | 20,000 | |||||||||||||
| Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Upfront license fee | 100,000 | |||||||||||||
| License and Sponsored Research Agreements [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| License and sponsored research agreement terms | Under the agreements, the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $805,000 and prior patent costs of up to $200,000. In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company also agreed to pay another $500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $10,000 to $50,000) for such year | |||||||||||||
| License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Reimbursement of research expenses | $ 805,000 | |||||||||||||
| Proceeds from convertible debt | 50,000 | |||||||||||||
| Patent costs | 200,000 | |||||||||||||
| Marketing approval expenses | 500,000 | |||||||||||||
| License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Cumulative sales | 300,000 | |||||||||||||
| Cumulative sales | 5,000,000 | 5,000,000 | ||||||||||||
| Regulatory marketing approval, expenses | 500,000 | |||||||||||||
| License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payment | 50,000 | 100,000 | ||||||||||||
| Shortfall payments | 10,000 | |||||||||||||
| License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payment | 5,000,000 | 5,000,000 | ||||||||||||
| Shortfall payments | 50,000 | |||||||||||||
| Sponsored Research Agreements And License [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| License costs | 0 | 1,000 | 0 | 1,000 | ||||||||||
| Research and development expenses | 0 | 0 | 0 | 0 | ||||||||||
| Sponsored Research Agreements And License [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| License costs | 0 | 22,000 | 0 | 76,000 | ||||||||||
| Research and development expenses | 0 | $ 0 | 0 | $ 0 | ||||||||||
| Co Development Agreement [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Marizyme agreement terms | the Company agreed to pay Marizyme a Funding Payments and an Exclusivity Fee of $200,000. The Exclusivity Fee of $200,000 and a Funding Payment of $500,000 was paid to Marizyme on April 12, 2024. The Exclusivity Fee entitled us to an exclusivity period until May 31, 2024 for purposes of proposing and outlining a broader strategic relationship with Marizyme with regard to Marizyme’s DuraGraft business. The Funding Payments are designed to provide financial support for commercialization of Marizyme’s DuraGraft™ vascular conduit solution, which is indicated for adult patients undergoing coronary artery bypass grafting surgeries and is intended for the flushing and storage of the saphenous vein grafts used in coronary artery bypass grafting surgery. In return for the Funding Payments the Company will receive quarterly a 33% payment in the nature of royalties on any Net Sales (as defined with a meaning tantamount to gross profit on net sales) of DuraGraft, capped at double the amount of the Funding Payment cash provided. No such payments-in-the-nature-of-royalties would accrue until after DuraGraft has been launched in the United States and a cumulative total of $500,000 of DuraGraft Net Sales have been made in the United States. During the nine months ended September 30, 2025 and the year ended December 31, 2024, the Company advanced $1,809,500 and $2,257,400, respectively, to Marizyme, against which Marizyme had previously delivered demand promissory notes to the Company. Accrued interest related to the Marizyme Notes as of September 30, 2025 and December 31, 2024 was $542,207 and $113,292, respectively, and interest income for the three months ended September 30, 2025 in the amount of $177,612 and for the nine months ended September 30, 2025 in the amount of $428,915 was recognized in other income in the consolidated statement of operations, and a $261,000 loan loss reserve was recorded in operations in the consolidated statement of operations (see Note 5 – Short-Term Note Receivable) | |||||||||||||
| Exclusivity Fee | $ 200,000 | |||||||||||||
| Debt funded to Marizyme | $ 500,000 | |||||||||||||
| Short term debt | 1,809,500 | 1,809,500 | $ 2,257,400 | |||||||||||
| Accrued interest | 542,207 | 542,207 | $ 113,292 | |||||||||||
| Other income recognized | $ 177,612 | 428,915 | ||||||||||||
| Loan loss reserve | $ 261,000 | |||||||||||||
| Upfront Payment [Member] | License Agreement [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Reimbursement of patent | $ 150,000 | |||||||||||||
| Phase 1 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payment | 50,000 | 100,000 | ||||||||||||
| Phase 2 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payment | 100,000 | 200,000 | ||||||||||||
| Phase 3 Clinical Trial [Member] | License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | ||||||||||||||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||||||||||||||
| Milestone payment | $ 150,000 | $ 350,000 | ||||||||||||